T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2017

  • ID: 4311797
  • Report
  • 74 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biotest AG
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • TaiMed Biologics Inc
  • United Biomedical Inc
  • MORE
T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2017'; T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 20 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - CD4 is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. It regulates T-cell activation. It induces the aggregation of lipid rafts. It acts as a receptor for human immunodeficiency virus-1, human Herpes virus 7/HHV-7. It is down regulated by HIV-1 Vpu.

The report 'T Cell Surface Glycoprotein CD4 - Pipeline Review, H1 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 2 and 7 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Metabolic Disorders and Undisclosed which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Encephalitis, Graft Versus Host Disease (GVHD), Influenza A Virus, H5N1 Subtype Infections, Malaria, Myocarditis, Severe Acute Respiratory Syndrome (SARS), Simplexvirus (HSV) Infections, Smallpox, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes), Unspecified and West Nile Virus Infections.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • The report reviews T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biotest AG
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • TaiMed Biologics Inc
  • United Biomedical Inc
  • MORE
  1. Introduction
  2. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Overview
  3. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Companies Involved in Therapeutics Development
  14. Biotest AG
  15. CEL-SCI Corp
  16. Fountain Biopharma Inc
  17. Immupharma Plc
  18. Inovio Pharmaceuticals Inc
  19. TaiMed Biologics Inc
  20. United Biomedical Inc
  21. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Drug Profiles
  22. 3BNC-117 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. CEL-1000 - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. forigerimod acetate - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. HIV vaccine 2 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. ibalizumab - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. ibalizumab biosimilar - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. M-48U1 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. MAX-16H5 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. Monoclonal Antibodies to Target CD4 and CD8 for Type 1 Diabetes - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. Monoclonal Antibody Conjugates to Target CD4 and HDAC for HIV-1 - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. N-6 - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. Recombinant Proteins for Immunology - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. Small Molecules to Activate CD4 for HIV - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. Small Molecules to Inhibit CD4 and MHC Class I for HIV - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. Small Molecules to Target CD4 for HIV - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. TMB-358 - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. TMB-360 - Drug Profile
  87. Product Description
  88. Mechanism Of Action
  89. R&D Progress
  90. tregalizumab - Drug Profile
  91. Product Description
  92. Mechanism Of Action
  93. R&D Progress
  94. UB-421 - Drug Profile
  95. Product Description
  96. Mechanism Of Action
  97. R&D Progress
  98. VRC-01 - Drug Profile
  99. Product Description
  100. Mechanism Of Action
  101. R&D Progress
  102. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Dormant Products
  103. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Discontinued Products
  104. T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Product Development Milestones
  105. Featured News & Press Releases
  106. May 17, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study
  107. May 03, 2017: Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
  108. Apr 25, 2017: United BioPharma selects GE Healthcare’s FlexFactory to build late-stage clinical and commercial production capacity for biopharmaceuticals
  109. Mar 02, 2017: Findings published in Nature Communications show that mRNA-LNP encoding a neutralizing antibody protect humanized mice from HIV challenge
  110. Feb 15, 2017: Theratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
  111. Feb 14, 2017: Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
  112. Jan 25, 2017: ImmuPharma: Update on Lupuzor Pivotal Phase III Study Full Analysis of Patient Recruitment
  113. Jan 17, 2017: Theratechnologies Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI
  114. Dec 22, 2016: ImmuPharma Provides Update on Lupuzor Pivotal Phase III Study
  115. Nov 10, 2016: Theratechnologies Announces Results from the Last Pivotal Phase III Trial of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab
  116. Nov 09, 2016: Antibody VRC01 Safe, Only Modest Effect in Controlling HIV Without Antiretroviral Therapy
  117. Nov 02, 2016: Market Studies on Ibalizumab for the United States Market
  118. Nov 01, 2016: Theratechnologies Announces Update from its Healthcare Analyst Day Meeting
  119. Oct 28, 2016: Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek
  120. Oct 24, 2016: Theratechnologies Announces End of Patient Treatment for Phase III Ibalizumab Trial
  121. Appendix
  122. Methodology
  123. Coverage
  124. Secondary Research
  125. Primary Research
  126. Expert Panel Validation
  127. Contact Us
  128. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by Biotest AG, H1
  12. Pipeline by CEL-SCI Corp, H1
  13. Pipeline by Fountain Biopharma Inc, H1
  14. Pipeline by Immupharma Plc, H1
  15. Pipeline by Inovio Pharmaceuticals Inc, H1
  16. Pipeline by TaiMed Biologics Inc, H1
  17. Pipeline by United Biomedical Inc, H1
  18. Dormant Products, H1
  19. Dormant Products, H1 2017 (Contd..1), H1
  20. Dormant Products, H1 2017 (Contd..2), H1
  21. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biotest AG
  • CEL-SCI Corp
  • Fountain Biopharma Inc
  • Immupharma Plc
  • Inovio Pharmaceuticals Inc
  • TaiMed Biologics Inc
  • United Biomedical Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll